Quantcast
Home > Quotes > MYGN
MYGN

Myriad Genetics, Inc. Common Stock (MYGN) Quote & Summary Data

$31.48
*  
0.22
0.69%
Get MYGN Alerts
*Delayed - data as of Nov. 21, 2018 10:53 ET  -  Find a broker to begin trading MYGN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MYGN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 31.54 / $ 31.60
1 Year Target
40
Today's High / Low
$ 32.10 / $ 31.38
Share Volume
87,315
50 Day Avg. Daily Volume
942,407
Previous Close
$ 31.70
52 Week High / Low
$ 50.44 / $ 27.27
Market Cap
2,353,507,791
P/E Ratio
40.36
Forward P/E (1y)
21.13
Earnings Per Share (EPS)
$ 0.78
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.92

Intraday Chart

Shares Traded

Share Volume:
87,315
50 Day Avg. Daily Volume:
942,407

P/E Ratio

P/E Ratio:
40.36
Forward P/E (1y):
21.13
Earnings Per Share (EPS):
$ 0.78

Trading Range

The current last sale of $31.48 is 15.44% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 32.10 $ 50.44
 Low: $ 31.38 $ 27.27

Company Description (as filed with the SEC)

We are one of the largest specialty molecular diagnostic laboratories in the world and since our founding in 1992, have tested over 3.0 million patients. We are headquartered in Salt Lake City, Utah and generated worldwide revenues of $772.6 million during our fiscal year ended June 30, 2018. We are a leading personalized medicine company acting as a trusted advisor to transform patient lives through pioneering molecular diagnostics. Through our proprietary technologies, we believe we are positioned to identify important disease genes, the proteins they produce, and the biological pathways in which they are involved to better understand the genetic basis of human disease. We believe that identifying these biomarkers (DNA, RNA and proteins) will enable us to develop novel molecular diagnostic tests that can provide important information to solve unmet medical needs.  ... More ...  


Risk Grade

Where does MYGN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 31.71
Open Date:
Nov. 21, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x